March 10, 2025
Keio University School of Medicine
Fujita Health University
A research group led by Senior Lecturer Kenta Masuda, Guest Associate Professor Koji Sakano, and Professor Wataru Yamagami of the Department of Obstetrics and Gynecology, Keio University School of Medicine, in collaboration with Professor Osamu Nagano and his colleagues at the Division of Gene Regulation, Cancer Research Center, Fujita Health University, has discovered that in refractory ovarian cancer without BRCA1/2 mutations, activation of the mTOR pathway is involved in treatment resistance and that adding mTOR inhibitors to standard treatment enhances the effects of chemotherapy. They also found that the p62 protein is a promising new biomarker for predicting treatment efficacy. The results of this research were published online in Cancer Letters on February 17, 2025. This is expected to become a new therapeutic strategy for refractory ovarian cancer in the future.
Please see below for the full press release.